Peroxisome proliferation-activated receptors (PPARs) are ligand-activated transcription factors that mainly regulate genes responsible for fatty acid (FA) and energy metabolism. There are three members of the PPAR family, PPAR-α, PPAR- β/δ and PPAR-γ. All three isoforms have therapeutic potential for treatment of cardiovascular disorders, and PPAR agonists are currently being actively studied in pre-clinical and clinical trials. PPAR γ agonists, main tissue expressing isoform, have potential to influence on inflammation processes, reduce oxidative stress, improve endothelial function and plays an important role in lipid metabolism. PPAR-γ agonists are used as insulin sensitizers for treatment of diabetes; however, there is accumulating evidence that their clinical application can be broadened. The wide spectrum of PPAR-γ activation effects may be beneficial for treatment of various cardiovascular conditions as atherosclerosis, hypertension and aortic aneurysm, including surgical interventions. In this Review we will discuss the implication of PPAR-γ in the cardiovascular system and potential role of PPAR-γ agonists in treatment of conditions associated with high cardiovascular risks.
Keywords: Peroxisome proliferation-activated receptor gamma (PPARγ), cardiovascular disorders, cardiovascular surgery, atherosclerosis.
Biological, Geometric and Biomechanical Factors Influencing Abdominal Aortic Aneurysm Rupture Risk: A Comprehensive Review
Recent Patents on Medical Imaging (Discontinued) Adipocytes and Abdominal Aortic Aneurysm: Putative Potential Role of Adipocytes in the Process of AAA Development
Current Drug Targets Molecular Genetics of Abdominal Aortic Aneurysm: Therapeutic Implications
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) Current Theories and Clinical Trial Evidence for Limiting Human Abdominal Aortic Aneurysm Growth
Current Drug Targets Automatic Brain Aneurysm Extraction in Angiography Videos Using Circlet Transform and a Modified Level Set Model
Current Medical Imaging Diabetes as a Negative Risk Factor for Abdominal Aortic Aneurysm – Does the Disease Aetiology or the Treatment Provide the Mechanism of Protection?
Current Vascular Pharmacology Statins: The Holy Grail of Abdominal Aortic Aneurysm (AAA) Growth Attenuation? A Systematic Review of the Literature
Current Vascular Pharmacology Intraventricular Recombinant Tissue Plasminogen Activator in Treatment of Aneurysmal Intraventricular Hemorrhage: A Meta-Analysis
Current Drug Targets Hypoperfusion of the Aortic Wall Secondary to Degeneration of Adventitial Vasa Vasorum Causes Abdominal Aortic Aneurysms
Current Drug Targets Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
Current Vascular Pharmacology Systemic Inflammatory Response, Bacterial Translocation and Nitric Oxide Donors
Inflammation & Allergy - Drug Targets (Discontinued) Early Cerebral Infarction Following Aneurysmal Subarachnoid Hemorrhage: Frequency, Risk Factors, Patterns, and Prognosis
Current Neurovascular Research Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews Ulnar Artery Thrombosis Due to Hypothenar Hammer Syndrome
Recent Patents on Cardiovascular Drug Discovery (Discontinued) A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Nifedipine Inhibits the Progression of An Experimentally Induced Cerebral Aneurysm in Rats with Associated Down-Regulation of NF-Kappa B Transcriptional Activity
Current Neurovascular Research The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis
Vascular Disease Prevention